Epizyme Eyes $124.5M Offering After Buying Back Cancer Drug
Epizyme Inc., a biopharmaceutical company developing cancer therapies, priced a $124.5 million public offering of shares on Tuesday, less than a week after the company announced it is reacquiring global rights...To view the full article, register now.
Already a subscriber? Click here to view full article